Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)

Friederike C. Althoff; Horst-Dieter Hummel; Konrad Kokowski; Timo Sabelhaus; Christian Grah; Stefan Zacharias; A. Fleitz; Martina Jänicke; Annika Groth; Paula Ludwig; Arnd Nusch; Marcel Reiser; Henning Pelz; Jörg Wiegand; Frank Griesinger; Michael Thomas; Wilfried E.E. Eberhardt; Martin Sebastian

doi:10.1016/j.ejca.2026.116265

Key Points

Institutional variability in genetic testing practices impacts patient care, revealing significant differences in approaches.
The analysis indicates that this variability is not explained by patient or tumor characteristics, implying other factors at play.
Observational analysis from the CRISP registry highlights the need for understanding genetic testing discrepancies across institutions.
Calls for standardized testing protocols could enhance patient outcomes and address existing inconsistencies in practice.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis reveals significant variability in genetic testing practices among institutions, suggesting a need for standardized approaches.

Abstract

Substantial institutional variability exists in AGA testing for NSCLC, which was unexplained by patient or tumor characteristics. This objective evaluation of institution-based variability in testing may emphasize the importance of practice patterns on patient care and may therefore provide an avenue for change.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Althoff et al. (2026) studied this question.

synapsesocial.com/papers/69a75f17c6e9836116a2a3be https://doi.org/10.1016/j.ejca.2026.116265

View Full Paper

Ask AI

Bookmark

Share

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading